Immunopathogenesis of hepatitis B virus recurrence after liver transplantation

Transplantation

Volumn 69, Issue 4, 2000, Pages 559-568

  Marinos, George ^a,b   Rossol, Siegbert ^a,c   Carucci, Patrizia ^a,d   Wong, Philip Y N ^a,e   Donaldson, Peter ^a   Hussain, Munther J ^a,f   Vergani, Diego ^a,f   Portmann, Bernard C ^a   Williams, Roger ^a,f   Naoumov, Nikolai V ^a,f,g  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c Department of Gastroenterology ^*  (Germany)

^d MOLINETTE HOSPITAL   (Italy)

^e AUCKLAND CITY HOSPITAL   (New Zealand)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HELPER CELL; HEPATITIS B; HUMAN; IMMUNOPATHOGENESIS; LIVER TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; T LYMPHOCYTE;

EID: 0034015514     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200002270-00017     Document Type: Article

References (49)

1. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol 1992; 14: 104.
2. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
3. Demetris AJ, Todo S, Van TD, et al. Evolution of hepatitis B virus liver disease after hepatic replacement: practical and theoretical considerations. Am J Pathol 1990; 137: 667.
4. Phillips MJ, Cameron R, Flowers MA, et al. Post-transplant recurrent hepatitis B viral liver disease: viral-burden, steatoviral, and fibroviral hepatitis B. Am J Pathol 1992; 140: 1295.
5. Konig V, Hopf U, Neuhaus P, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553.
6. Chisari FV, Ferrari C, Mondelli MU. Hepatitis B virus structure and biology. Microb Pathog 1989; 6: 311.
7. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29.
8. Moriyama T, Guilhot S, Klopchin K, et al. Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 1990; 248: 361.
9. Bertoletti A, Ferrari C, Fiaccadori F, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 1991; 88: 10445.
10. Guidotti LG, Ando K, Hobbs MV, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764.
11. Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 1981; 81; 987.
12. Lau JYN, Bain VG, Smith HM, Alexander GJM, Williams R. Modulation of hepatitis-B viral-antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation 1992; 53: 894.
13. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 36.
14. Hanson RG, Peters MG, Hoofnagle JH. Effects of immunosuppressive therapy with prednisolone on B and T lymphocyte function in patients with chronic type B hepatitis. Hepatology 1986; 6: 173.
15. Gassel HJ, Engemann R, Thiede A, Hamelmann H. Replacement of donor Kupffer cells by recipient cells after orthotopic rat liver transplantation. Transplant Proc 1987; 19: 353.
16. Gouw AS, Houthoff HJ, Huitema S, Beelen JM, Gips CH, Poppema S. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 1987; 43: 291.
17. Steinhoff G, Wonigeit K, Sorg C, Behrend M, Mues B, Pichlmayr R. Patterns of macrophage immigration and differentiation in human liver grafts. Transplant Proc 1989; 21: 398.
18. Ferrari C, Penna A, Bertoletti A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442.
19. Tsai SL, Chen PJ, Lai MY, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. J Clin Invest 1992; 89: 87.
20. Marinos G, Torre F, Chokshi S, et al. Induction of T helper cell response to HBcAg in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology 1995; 20: 1040.
21. + T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants. Hepatology 1995; 22: 61.
22. Gilles PN, Guerrette DL, Ulevitch RJ, Schreiber RD, Chisari FV. HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology 1992; 16: 655.
23. Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 1989; 10: 769.
24. Yoshioka K, Kakumu S, Arao M, et al. Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease. J Clin Pathol 1990; 43: 298.
25. Sheron N, Lau JYN, Daniels H, et al. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol 1991; 12: 241.
26. Volpes R, van den Oord JJ, De Vos R, Desmet VJ. Hepatic expression of type A and type B receptors for tumor necrosis factor. J Hepatol 1992; 14: 361.
27. Marinos G, Naoumov NV, Rossol S, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology 1995; 108: 1453.
28. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151.
29. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513.
30. Donaldson P, Underhill J, Doherty D, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection. Hepatology 1993; 17: 1008.
31. Rossol S, Voth R, Laubenstein HP, et al. Interferon production in patients infected with HIV-1. J Infect Dis 1989; 159: 815.
32. Hussain MJ, Mustafa A, Gallati H, Mowat AP, Mieli Vergani G, Vergani D. Cellular expression of tumour necrosis factor-alpha and interferon-gamma in the liver biopsies of children with chronic liver disease. J Hepatol 1994; 21: 816.
33. + T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995; 69: 3358.
34. Missale G, Brems JJ, Takiff H, Pockros PJ, Chisari FV. Human leukocyte antigen class I-independent pathways may contribute to hepatitis B virus-induced liver disease after liver transplantation. Hepatology 1993; 18: 491.
35. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815.
36. Calmus Y, Hannoun L, Dousset B, et al. HLA class I matching is responsible for the hepatic lesions in recurrent viral hepatitis B after liver transplantation. Transplant Proc 1990; 22: 2311.
37. Manez R, Mateo R, Tabasco J, Kusne S, Starzl TE, Duquesnoy RJ. The influence of HLA donor-recipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 1995; 59: 640.
38. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell 1994; 76: 241.
39. Pujol-Borrell R, Todd I, Doshi M, et al. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin. Nature 1987; 326: 304.
40. Shinagawa T, Yoshioka K, Kakumu S, et al. Apoptosis in cultured rat hepatocytes: the effects of tumour necrosis factor alpha and interferon gamma. J Pathol 1991; 165: 247.
41. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4: 754.
42. Lau JY, Bain VG, Davies SE, et al. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis. Gastroenterology 1992; 102: 956.
43. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-gamma induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol 1989; 135: 121.
44. Thornhill MH, Wellicome SM, Mahiouz DL, Lanchbury JS, Kyan Aung U, Haskard DO. Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells: the contribution of vascular cell adhesion molecule-1-dependent and -independent binding mechanisms. J Immunol 1991; 146: 592.
45. Adamson GM, Billings RE. Cytokine toxicity and induction of NO synthase activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol 1993; 119: 100.
46. Vouldoukis I, Riveros Moreno V, et al. The killing of Leishmania major by human macrophages is mediated by nitric oxide induced after ligation of the Fc epsilon RII/CD23 surface antigen. Proc Natl Acad Sci USA 1995; 92: 7804.
47. Grell M, Zimmermann G, Hulser D, Pfizenmaier K, Scheurich P. TNF receptors TR60 and TR80 can mediate apoptosis via induction of distinct signal pathways. J Immunol 1994; 153: 1963.
48. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25.
49. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150.